Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Non Operating Income (2023 - 2025)

Historic Other Non Operating Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$29000.0.

  • Monte Rosa Therapeutics' Other Non Operating Income rose 8104.58% to -$29000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 52082.19%. This contributed to the annual value of $416000.0 for FY2024, which is 14473.12% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Other Non Operating Income stood at -$29000.0, which was up 8104.58% from $1.4 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Other Non Operating Income high stood at $1.4 million for Q2 2025, and its period low was -$779000.0 during Q4 2023.
  • Its 3-year average for Other Non Operating Income is $92727.3, with a median of -$29000.0 in 2025.
  • In the last 5 years, Monte Rosa Therapeutics' Other Non Operating Income plummeted by 66666.67% in 2024 and then soared by 272264.15% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Other Non Operating Income (Quarter) stood at -$779000.0 in 2023, then soared by 100.26% to $2000.0 in 2024, then plummeted by 1550.0% to -$29000.0 in 2025.
  • Its last three reported values are -$29000.0 in Q3 2025, $1.4 million for Q2 2025, and $173000.0 during Q1 2025.